Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Correction: Using HSV-1 Genome Phylogenetics to Track Past Human Migrations.

Kolb AW, Ané C, Brandt CR.

PLoS One. 2019 May 30;14(5):e0217890. doi: 10.1371/journal.pone.0217890. eCollection 2019.

2.

Assessment of selenium bioaccumulation in lactic acid bacteria.

Mörschbächer AP, Dullius A, Dullius CH, Brandt CR, Kuhn D, Brietzke DT, José Malmann Kuffel F, Etgeton HP, Altmayer T, Gonçalves TE, Schweizer YA, Oreste EQ, Ribeiro AS, Lehn DN, Volken de Souza CF, Hoehne L.

J Dairy Sci. 2018 Dec;101(12):10626-10635. doi: 10.3168/jds.2018-14852. Epub 2018 Oct 11. Erratum in: J Dairy Sci. 2019 Feb;102(2):1883.

PMID:
30316597
3.

Toll-like receptors 4, 5, 6 and 7 are constitutively expressed in non-human primate retinal neurons.

Sauter MM, Kolb AW, Brandt CR.

J Neuroimmunol. 2018 Sep 15;322:26-35. doi: 10.1016/j.jneuroim.2018.06.007. Epub 2018 Jun 11.

PMID:
29954626
4.

Genomic, Recombinational and Phylogenetic Characterization of Global Feline Herpesvirus 1 Isolates.

Lewin AC, Kolb AW, McLellan GJ, Bentley E, Bernard KA, Newbury SP, Brandt CR.

Virology. 2018 May;518:385-397. doi: 10.1016/j.virol.2018.03.018. Epub 2018 Mar 30.

5.

Proteasome Inhibition Increases the Efficiency of Lentiviral Vector-Mediated Transduction of Trabecular Meshwork.

Aktas Z, Rao H, Slauson SR, Gabelt BT, Larsen IV, Sheridan RTC, Herrnberger L, Tamm ER, Kaufman PL, Brandt CR.

Invest Ophthalmol Vis Sci. 2018 Jan 1;59(1):298-310. doi: 10.1167/iovs.17-22074.

6.

Phylogenetic and recombination analysis of the herpesvirus genus varicellovirus.

Kolb AW, Lewin AC, Moeller Trane R, McLellan GJ, Brandt CR.

BMC Genomics. 2017 Nov 21;18(1):887. doi: 10.1186/s12864-017-4283-4.

7.

Effect of a Soluble Epoxide Hydrolase Inhibitor, UC1728, on LPS-Induced Uveitis in the Rabbit.

McLellan GJ, Aktas Z, Hennes-Beean E, Kolb AW, Larsen IV, Schmitz EJ, Clausius HR, Yang J, Hwang SH, Morisseau C, Inceoglu B, Hammock BD, Brandt CR.

J Ocul Biol. 2016 Jan;4(1). doi: 10.13188/2334-2838.1000024. Epub 2016 Jan 12.

8.

A Mouse Model of Multi-Drug Resistant Staphylococcus aureus-induced Ocular Disease.

Broekema NM, Larsen IV, Naruzawa ES, Filutowicz M, Kolb AW, Teixeira LB, Brandt CR.

J Ocul Biol. 2016 Nov;4(2). doi: 10.13188/2334-2838.1000026. Epub 2016 Nov 10.

9.
10.

Both CD8+ and CD4+ T Cells Contribute to Corneal Clouding and Viral Clearance following Vaccinia Virus Infection in C57BL/6 Mice.

Larsen IV, Clausius H, Kolb AW, Brandt CR.

J Virol. 2016 Jun 24;90(14):6557-6572. doi: 10.1128/JVI.00570-16. Print 2016 Jul 15.

11.

Primate neural retina upregulates IL-6 and IL-10 in response to a herpes simplex vector suggesting the presence of a pro-/anti-inflammatory axis.

Sauter MM, Brandt CR.

Exp Eye Res. 2016 Jul;148:12-23. doi: 10.1016/j.exer.2016.05.003. Epub 2016 May 8.

12.

Quantitative Trait Locus Based Virulence Determinant Mapping of the HSV-1 Genome in Murine Ocular Infection: Genes Involved in Viral Regulatory and Innate Immune Networks Contribute to Virulence.

Kolb AW, Lee K, Larsen I, Craven M, Brandt CR.

PLoS Pathog. 2016 Mar 10;12(3):e1005499. doi: 10.1371/journal.ppat.1005499. eCollection 2016 Mar.

13.

Recombination Analysis of Herpes Simplex Virus 1 Reveals a Bias toward GC Content and the Inverted Repeat Regions.

Lee K, Kolb AW, Sverchkov Y, Cuellar JA, Craven M, Brandt CR.

J Virol. 2015 Jul;89(14):7214-23. doi: 10.1128/JVI.00880-15. Epub 2015 Apr 29.

14.

Genomic, phylogenetic, and recombinational characterization of herpes simplex virus 2 strains.

Kolb AW, Larsen IV, Cuellar JA, Brandt CR.

J Virol. 2015 Jun;89(12):6427-34. doi: 10.1128/JVI.00416-15. Epub 2015 Apr 8.

15.

Viral Vector Effects on Exoenzyme C3 Transferase-Mediated Actin Disruption and on Outflow Facility.

Slauson SR, Peters DM, Schwinn MK, Kaufman PL, Gabelt BT, Brandt CR.

Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2431-8. doi: 10.1167/iovs.14-15909.

16.

Peptide therapeutics for treating ocular surface infections.

Brandt CR.

J Ocul Pharmacol Ther. 2014 Nov;30(9):691-9. doi: 10.1089/jop.2014.0089. Epub 2014 Sep 24. Review.

17.

Oligonucleotides designed to inhibit TLR9 block Herpes simplex virus type 1 infection at multiple steps.

Sauter MM, Gauger JJ, Brandt CR.

Antiviral Res. 2014 Sep;109:83-96. doi: 10.1016/j.antiviral.2014.06.015. Epub 2014 Jul 1.

18.

Prospects for lentiviral vector mediated prostaglandin F synthase gene delivery in monkey eyes in vivo.

Lee ES, Rasmussen CA, Filla MS, Slauson SR, Kolb AW, Peters DM, Kaufman PL, Gabelt BT, Brandt CR.

Curr Eye Res. 2014 Sep;39(9):859-70. doi: 10.3109/02713683.2014.884593. Epub 2014 Feb 21. Review.

19.

Using HSV-1 genome phylogenetics to track past human migrations.

Kolb AW, Ané C, Brandt CR.

PLoS One. 2013 Oct 16;8(10):e76267. doi: 10.1371/journal.pone.0076267. eCollection 2013. Erratum in: PLoS One. 2019 May 30;14(5):e0217890.

20.

Characterization and cytotoxic activity of sulfated derivatives of polysaccharides from Agaricus brasiliensis.

Cardozo FT, Camelini CM, Cordeiro MN, Mascarello A, Malagoli BG, Larsen IV, Rossi MJ, Nunes RJ, Braga FC, Brandt CR, Simões CM.

Int J Biol Macromol. 2013 Jun;57:265-72. doi: 10.1016/j.ijbiomac.2013.03.026. Epub 2013 Mar 17.

21.

In vivo anti-herpes simplex virus activity of a sulfated derivative of Agaricus brasiliensis mycelial polysaccharide.

Cardozo FT, Larsen IV, Carballo EV, Jose G, Stern RA, Brummel RC, Camelini CM, Rossi MJ, Simões CM, Brandt CR.

Antimicrob Agents Chemother. 2013 Jun;57(6):2541-9. doi: 10.1128/AAC.02250-12. Epub 2013 Mar 18.

22.

A cationic peptide, TAT-Cd°, inhibits herpes simplex virus type 1 ocular infection in vivo.

Jose GG, Larsen IV, Gauger J, Carballo E, Stern R, Brummel R, Brandt CR.

Invest Ophthalmol Vis Sci. 2013 Feb 5;54(2):1070-9. doi: 10.1167/iovs.12-10250.

23.

Antiviral activity of the EB peptide against zoonotic poxviruses.

Altmann SE, Brandt CR, Jahrling PB, Blaney JE.

Virol J. 2012 Jan 6;9:6. doi: 10.1186/1743-422X-9-6.

24.

Ocular distribution, spectrum of activity, and in vivo viral neutralization of a fully humanized anti-herpes simplex virus IgG Fab fragment following topical application.

Berdugo M, Larsen IV, Abadie C, Deloche C, Kowalczuk L, Touchard E, Dubielzig R, Brandt CR, Behar-Cohen F, Combette JM.

Antimicrob Agents Chemother. 2012 Mar;56(3):1390-402. doi: 10.1128/AAC.05145-11. Epub 2011 Dec 27.

25.

Multiplex sequencing of seven ocular herpes simplex virus type-1 genomes: phylogeny, sequence variability, and SNP distribution.

Kolb AW, Adams M, Cabot EL, Craven M, Brandt CR.

Invest Ophthalmol Vis Sci. 2011 Nov 25;52(12):9061-73. doi: 10.1167/iovs.11-7812.

26.

Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine.

Jones JC, Settles EW, Brandt CR, Schultz-Cherry S.

Vaccine. 2011 Oct 13;29(44):7696-703. doi: 10.1016/j.vaccine.2011.07.133. Epub 2011 Aug 10.

27.

Sequence variation in the herpes simplex virus U(S)1 ocular virulence determinant.

Kolb AW, Schmidt TR, Dyer DW, Brandt CR.

Invest Ophthalmol Vis Sci. 2011 Jun 28;52(7):4630-8. doi: 10.1167/iovs.10-7032.

28.

Evaluation of therapeutic interventions for vaccinia virus keratitis.

Altmann S, Brandt CR, Murphy CJ, Patnaikuni R, Takla T, Toomey M, Nesbit B, McIntyre K, Covert J, Dubielzig R, Leatherberry G, Adkins E, Kodihalli S.

J Infect Dis. 2011 Mar 1;203(5):683-90. doi: 10.1093/infdis/jiq103. Epub 2011 Jan 28.

29.

Identification of the minimal active sequence of an anti-influenza virus peptide.

Jones JC, Settles EW, Brandt CR, Schultz-Cherry S.

Antimicrob Agents Chemother. 2011 Apr;55(4):1810-3. doi: 10.1128/AAC.01428-10. Epub 2011 Jan 10.

30.

A cationic TAT peptide inhibits Herpes simplex virus type 1 infection of human corneal epithelial cells.

Larsen IV, Brandt CR.

J Ocul Pharmacol Ther. 2010 Dec;26(6):541-7. doi: 10.1089/jop.2010.0076. Epub 2010 Oct 28.

31.

The virucidal EB peptide protects host cells from herpes simplex virus type 1 infection in the presence of serum albumin and aggregates proteins in a detergent-like manner.

Bultmann H, Girdaukas G, Kwon GS, Brandt CR.

Antimicrob Agents Chemother. 2010 Oct;54(10):4275-89. doi: 10.1128/AAC.00495-10. Epub 2010 Jul 19.

32.

A quantitative rabbit model of vaccinia keratitis.

Altmann S, Emanuel A, Toomey M, McIntyre K, Covert J, Dubielzig RR, Leatherberry G, Murphy CJ, Kodihalli S, Brandt CR.

Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4531-40. doi: 10.1167/iovs.09-5106. Epub 2010 Apr 7.

33.

Kinetics of immune cell infiltration in vaccinia virus keratitis.

Altmann S, Toomey M, Nesbit B, McIntyre K, Covert J, Dubielzig RR, Leatherberry G, Adkins E, Murphy CJ, Brandt CR.

Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4541-8. doi: 10.1167/iovs.09-5107. Epub 2010 Apr 7.

34.

COCH transgene expression in cultured human trabecular meshwork cells and its effect on outflow facility in monkey organ cultured anterior segments.

Lee ES, Gabelt BT, Faralli JA, Peters DM, Brandt CR, Kaufman PL, Bhattacharya SK.

Invest Ophthalmol Vis Sci. 2010 Apr;51(4):2060-6. doi: 10.1167/iovs.09-4521. Epub 2009 Nov 20.

35.

Gene therapy targeting glaucoma: where are we?

Liu X, Rasmussen CA, Gabelt BT, Brandt CR, Kaufman PL.

Surv Ophthalmol. 2009 Jul-Aug;54(4):472-86. doi: 10.1016/j.survophthal.2009.04.003. Review.

36.

Inhibition of Vaccinia virus entry by a broad spectrum antiviral peptide.

Altmann SE, Jones JC, Schultz-Cherry S, Brandt CR.

Virology. 2009 Jun 5;388(2):248-59. doi: 10.1016/j.virol.2009.03.023. Epub 2009 Apr 22.

37.

Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection.

Akkarawongsa R, Pocaro NE, Case G, Kolb AW, Brandt CR.

Antimicrob Agents Chemother. 2009 Mar;53(3):987-96. doi: 10.1128/AAC.00793-08. Epub 2008 Dec 22.

38.

H-1152 effects on intraocular pressure and trabecular meshwork morphology of rat eyes.

Yu M, Chen X, Wang N, Cai S, Li N, Qiu J, Brandt CR, Kaufman PL, Liu X.

J Ocul Pharmacol Ther. 2008 Aug;24(4):373-9. doi: 10.1089/jop.2008.0029.

39.

Inhibition of herpes simplex virus type 1 infection by cationic beta-peptides.

Akkarawongsa R, Potocky TB, English EP, Gellman SH, Brandt CR.

Antimicrob Agents Chemother. 2008 Jun;52(6):2120-9. doi: 10.1128/AAC.01424-07. Epub 2008 Apr 7.

41.

Evaluation of a theta-defensin in a Murine model of herpes simplex virus type 1 keratitis.

Brandt CR, Akkarawongsa R, Altmann S, Jose G, Kolb AW, Waring AJ, Lehrer RI.

Invest Ophthalmol Vis Sci. 2007 Nov;48(11):5118-24.

PMID:
17962464
42.

Ocular drug delivery: molecules, cells, and genes.

Liu X, Brandt CR, Rasmussen CA, Kaufman PL.

Can J Ophthalmol. 2007 Jun;42(3):447-54. Review.

PMID:
17508043
43.
44.
45.

Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells.

Jones JC, Turpin EA, Bultmann H, Brandt CR, Schultz-Cherry S.

J Virol. 2006 Dec;80(24):11960-7. Epub 2006 Sep 27.

46.

Corneal toxicity of cell-penetrating peptides that inhibit Herpes simplex virus entry.

Akkarawongsa R, Cullinan AE, Zinkel A, Clarin J, Brandt CR.

J Ocul Pharmacol Ther. 2006 Aug;22(4):279-89.

PMID:
16910869
47.
48.

The role of viral and host genes in corneal infection with herpes simplex virus type 1.

Brandt CR.

Exp Eye Res. 2005 May;80(5):607-21. Review.

PMID:
15862167
49.

Evaluation of the antitumor effects of Herpes simplex virus lacking ribonucleotide reductase in a murine retinoblastoma model.

Cullinan AE, Lindstrom MJ, Sabet S, Albert DM, Brandt CR.

Curr Eye Res. 2004 Aug-Sep;29(2-3):167-72.

PMID:
15512963
50.

Virulence genes in herpes simplex virus type 1 corneal infection.

Brandt CR.

Curr Eye Res. 2004 Aug-Sep;29(2-3):103-17. Review. No abstract available.

PMID:
15512957

Supplemental Content

Loading ...
Support Center